| Size | Price | |
|---|---|---|
| 100mg | ||
| Other Sizes |
| Targets |
Fmoc-N-Me-Val-OH does not have a specific biological target as it is a chemical reagent used for peptide synthesis rather than a drug. The compound functions as a building block in solid-phase peptide synthesis (SPPS). The Fmoc group serves as a temporary protecting group for the amino functionality, allowing selective deprotection and coupling during peptide chain assembly. The N-methylation at the valine residue introduces conformational constraints and enhances the metabolic stability of the resulting peptides. The compound is used to incorporate N-methyl-L-valine into peptide sequences for research applications.
|
|---|---|
| ln Vitro |
In vitro activity of Fmoc-N-Me-Val-OH is not applicable as the compound is a chemical reagent rather than a bioactive compound. Its utility is in peptide synthesis where it serves as a building block for incorporating N-methyl-L-valine into peptide sequences. The N-methylation of valine residues in peptides can alter their conformation, proteolytic stability, and biological activity. The compound's role is in the preparation of modified peptides for research applications rather than in direct biological assays.
|
| ln Vivo |
In vivo activity of Fmoc-N-Me-Val-OH is not applicable as the compound is a chemical reagent used for peptide synthesis rather than a therapeutic compound. It is not administered to animals or humans for pharmacological studies. Its utility is limited to laboratory-scale peptide synthesis. The compound is not intended for in vivo applications and is used exclusively as a research reagent for the preparation of N-methylated peptides.
|
| Enzyme Assay |
The in vitro assay for Fmoc-N-Me-Val-OH is not applicable as the compound is a chemical reagent rather than a bioactive compound. For quality control, the compound is analyzed by HPLC to verify purity (≥98.0%) and by optical rotation to confirm enantiomeric purity (-65.0deg to -71.0deg, c=1, DMF). Melting point determination (186-191degC) is used for identity confirmation. These analytical methods ensure the compound's suitability for use in peptide synthesis. No biological assays are performed as the compound is not a drug.
|
| Cell Assay |
In vitro cellular assays for Fmoc-N-Me-Val-OH are not applicable as the compound is a chemical reagent for peptide synthesis rather than a bioactive compound. The compound is not used in cell-based assays as it is not designed to have biological activity. Its role is in the preparation of modified peptides, which may then be used in cellular assays. The compound itself is not tested in cellular systems. Standard laboratory safety precautions for handling chemical reagents should be followed.
|
| Animal Protocol |
In vivo animal studies for Fmoc-N-Me-Val-OH are not applicable as the compound is a chemical reagent for peptide synthesis rather than a therapeutic compound. It is not administered to animals for pharmacological studies. The compound is used exclusively in laboratory settings for peptide synthesis. Its utility is in the preparation of N-methylated peptides that may subsequently be studied in animal models, but the compound itself is not the subject of in vivo studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-N-Me-Val-OH are not applicable as the compound is a chemical reagent for peptide synthesis rather than a therapeutic compound. The compound has a molecular weight of 353.41 g/mol and a molecular formula of C21H23NO4. It is not intended for in vivo administration, so pharmacokinetic parameters are not relevant. The compound should be stored under appropriate conditions to maintain stability. For laboratory use, standard handling procedures for Fmoc-protected amino acids are followed.
|
| Toxicity/Toxicokinetics |
Toxicology data for Fmoc-N-Me-Val-OH are not extensively reported, as the compound is a chemical reagent rather than a therapeutic compound. Standard safety precautions for handling chemical reagents should be followed. The compound is not intended for human or therapeutic use. No specific toxicity data, including LD50 values, are available. For laboratory use, appropriate personal protective equipment should be worn when handling the compound. The compound is for research use only.
|
| References | |
| Additional Infomation |
Fmoc-N-Me-Val-OH (CAS# 84000-11-3) is a modified amino acid derivative containing the N-terminal Fmoc protecting group and a methyl substitution at the valine residue. It has a molecular formula of C21H23NO4 and a molecular weight of 353.41 g/mol. The compound is also known as Fmoc-N-methyl-L-valine or N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valine. It appears as a white to off-white solid powder with ≥98.0% purity. The compound is used as a building block in solid-phase peptide synthesis for incorporating N-methyl-L-valine into peptides.
|
| Molecular Formula |
C21H23NO4
|
|---|---|
| Molecular Weight |
353.4116
|
| Exact Mass |
353.162
|
| CAS # |
84000-11-3
|
| PubChem CID |
978328
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
527.6±29.0 °C at 760 mmHg
|
| Melting Point |
187-190ºC
|
| Flash Point |
272.9±24.3 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
4.91
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
498
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(C1C2C=CC=CC=2C2C=CC=CC1=2)OC(=O)N(C)[C@H](C(=O)O)C(C)C
|
| InChi Key |
YCXXXPZNQXXRIG-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C21H23NO4/c1-13(2)19(20(23)24)22(3)21(25)26-12-18-16-10-6-4-8-14(16)15-9-5-7-11-17(15)18/h4-11,13,18-19H,12H2,1-3H3,(H,23,24)/t19-/m0/s1
|
| Chemical Name |
(2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~141.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8296 mL | 14.1479 mL | 28.2957 mL | |
| 5 mM | 0.5659 mL | 2.8296 mL | 5.6591 mL | |
| 10 mM | 0.2830 mL | 1.4148 mL | 2.8296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
